Cargando…
Anti-VEGF Cancer Therapy in Nephrology Practice
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established....
Autor principal: | Izzedine, Hassan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158308/ https://www.ncbi.nlm.nih.gov/pubmed/25210627 http://dx.doi.org/10.1155/2014/143426 |
Ejemplares similares
-
Bone biopsy in nephrology practice
por: Barreto, Fellype de Carvalho, et al.
Publicado: (2018) -
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011) -
Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021) -
Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010) -
Sarcopenia and Frailty: Challenges in Mainstream Nephrology Practice
por: Wong, Limy, et al.
Publicado: (2021)